Pre-market Hot Trades in US Stocks
Aevex is up 12.24% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 21, Aevex's stock price surged more than double in the first two trading days after its IPO, continuing the momentum of newly listed defense technology companies. The stock rose 49% on Monday to $40.25, above last week's IPO price of $20 per share. The stock closed up over 24% on Monday to $33.41, with a cumulative increase of over 67% since its listing. As of the time of writing, the stock rose nearly 15% in after-hours trading on Monday. Source: Zhitong Finance
</li>
<li>
On April 21, the military drone manufacturer Aevex saw its stock price rise nearly 53% to $41.18 the day after its listing on the US stock market. Based on Aevex's listing price of $20, the stock price has doubled within two days. Source: Zhitong Finance
</li>
<li>
On April 21, Aevex's stock price doubled within two trading days, becoming one of the standout defense technology companies since its recent listing. The company is supported by Madison Dearborn Partners, and its Class A shares surged 49% on Monday to $40.25, doubling from last week's IPO price of $20. Source: Zhitong Finance. The surge in IPOs of defense technology companies has increased investor interest.
</li>
</ol>
Theriva Biologics is down 11.78% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 18, Theriva Biologics announced that it would present data from the Phase 2B clinical trial of VCN-01 in metastatic pancreatic cancer at the AACR 2026 annual meeting. This news attracted market attention, leading to stock price fluctuations.
</li>
<li>
On April 20, the company stated that it had reached an agreement with the US FDA and the European Medicines Agency regarding the pivotal Phase 3 clinical trial of VCN-01 in first-line metastatic pancreatic cancer patients. This move is seen as an important milestone in the company's R&amp;D progress, impacting the stock price.
</li>
<li>
On April 18, data released by Theriva Biologics showed that the combination of VCN-01 with chemotherapy drugs could improve overall survival and progression-free survival. This result has enhanced market confidence in the potential of its products, driving the stock price up. The biotechnology sector has been volatile recently, and caution is advised for investors.
</li>
</ol>
Top Gainers in Pre-market US Stocks
SciSparc is up 70.69% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Baiya is up 58.60% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation
Aspire Biopharma pre-market rose 44.56%. Based on recent key news:
<ol>
<li>
On April 20, Aspire Biopharma released a press release announcing that its platform can be applied to various active pharmaceutical ingredients, nutritional supplements, and innovative products, such as the BUZZ BOMB caffeine formula. This news sparked market interest in its product potential, driving the stock price up.
</li>
<li>
On April 20, Aspire Biopharma submitted an 8-K filing to the SEC. Although there may be inaccuracies in the information contained in the filing, the market reacted positively to its disclosures, further boosting the stock price.
</li>
<li>
On April 20, technical sentiment signals indicated a sell, but market interest in its innovative products may have offset this negative signal, leading to a significant rise in stock price. The biopharmaceutical industry has been active recently, with noticeable capital inflows
</li>
</ol>

AVEX

TOVX

Aevex pre-market up 12.24%; Theriva Biologics pre-market down 11.78%; SciSparc pre-market up 70.69%; Baiya pre-market up 58.60%; Aspire Biopharma pre-market up 44.56%

Pre-market hot trades in US stocks: Aevex up 12.24% pre-market; Theriva Biologics down 11.78% pre-market